Compounds > gp 4
Page last updated: 2024-11-11

gp 4

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GP 4: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6439597
MeSH IDM0163362

Synonyms (5)

Synonym
81746-15-8
4-cinnamyl-1-piperazinecarboxamidine
1-piperazinecarboxamidine, 4-cinnamyl-
gp 4
1-piperazinecarboxidamide, 4-(3-phenyl-2-propenyl)-

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" PKs from rats dosed with a (14)C-labeled microdose versus a (14)C-labeled pharmacological dose displayed dose linearity."( Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats.
Lao, V; Malfatti, MA; Ong, VS; Ramos, CL; Turteltaub, KW, 2014)		0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (23.53)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (5.88)24.3611
2020's12 (70.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.09 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index5.50 (4.65)
Search Engine Demand Index70.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		1.97101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
orlistat
Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.		2.610beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Adenoma, Basal Cell
[description not available]		02.610
Condition, Preneoplastic
[description not available]		02.610
Colorectal Cancer
[description not available]		02.610
Local Neoplasm Recurrence
[description not available]		03.0120
Adenoma
A benign epithelial tumor with a glandular organization.		02.610
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.		02.610
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.610
Cancer of Prostate
[description not available]		03.330
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		03.330
Orthopedic Disorders
[description not available]		02.610
Diseases, Occupational
[description not available]		02.610
Musculoskeletal Diseases
Diseases of the muscles and their associated ligaments and other connective tissue and of the bones and cartilage viewed collectively.		02.610
Blue-Eared Pig Disease
[description not available]		03.1130
Swine Diseases
Diseases of domestic swine and of the wild boar of the genus Sus.		02.610
Testicular Diseases
Pathological processes of the TESTIS.		02.610
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		02.610
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9710